Fundraising Fox
Matinas BioPharma Holdings
NYSE: MTNBBedminster, US · Founded 2013 · Delaware corporation
Find your way into Matinas BioPharma Holdings
Sign up to see every warm intro you have to Matinas BioPharma Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Matinas BioPharma Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Matinas BioPharma develops a Lipid Nano-Crystal (LNC) drug delivery platform that enables oral, intracellular delivery of small molecules and oligonucleotides. Its lead product MAT2203 is an amphotericin B formulation, alongside discovery programs in oncology and inflammation.
Founders & leadership
Matinas BioPharma Holdings was founded in 2013 by Roelof Rongen and Jerome D. Jabbour.
RR
Roelof RongenCo-founderRoelof Rongen has over 25 years of experience in pharmaceutical R&D and commercial development across oncology, cardiometabolic, autoimmune, and infectious diseases, including roles on blockbuster drugs Humira and Lovaza, and currently serves as an executive officer and director at Matinas BioPharma Holdings.
JD
Jerome D. JabbourCo-founder, Chairman & Chief Executive Officer
GB
George BobotasExecutive
GG
Gary GaglioneExecutive
AA
Abdel A. FawzyExecutiveAbdel A. Fawzy is an Executive Officer at Matinas BioPharma Holdings with extensive experience in pharmaceutical drug development, manufacturing, and regulatory submissions from early stage through commercialization, including scale-up, process development, and CMC strategy.
DF
Douglas F. KlingSr. VP Clinical Development & Project Management2015–2021Douglas F. Kling is an Executive Officer at Matinas BioPharma Holdings, where he leads clinical development and regulatory strategy for the company's lipid nano-crystal drug delivery platform. His background includes managing cross-functional teams in clinical trial execution, regulatory submissions to global authorities, and clinical operations management.
KA
Keith A. KucinskiChief Financial Officer2019–2026CFO of Matinas BioPharma, a company developing a lipid nano-crystal drug delivery platform for oral and intracellular delivery of small molecules and oligonucleotides. He brings finance and accounting experience across private equity, public companies, and founder-led organizations.
Board
AS
Adam SternBoard director
RS
Robin SmithBoard director
EE
Eric EndeBoard director
ED
Evelyn D'AnBoard director
MW
Matthew WiklerBoard director
Reported raises · per SEC filings
Form D private placements$31.5M disclosed across 4 rounds · 2015–2025
▶$1.6MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
▶$1.6MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robin SmithDirector
- Eric EndeDirector
- Jerome JabbourExecutive Officer, Director
- Evelyn D'AnDirector
- Keith KucinskiExecutive Officer
- Matthew WiklerDirector
- Natasha GiordanoDirector
- Offering amount
- $3.3M
- Amount sold
- $1.6M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.5MraisedJan 2017 · 270 investors · BiotechnologyRule 506(b)
▶$15.5MraisedJan 2017 · 270 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abdel A. FawzyExecutive Officer
- James ScibettaDirector
- Jerome JabbourExecutive Officer
- Douglas F. KlingExecutive Officer
- Stefano FerrariDirector
- Raphael J. ManninoExecutive Officer
- Herbert ConradDirector
- Adam SternDirector
- Gary GaglioneExecutive Officer
- Roelof RongenExecutive Officer, Director
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- Sales commissions
- $710K
- Placement agents
- Aegis Capital Corp.
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$4.4MraisedAug 2016 · 34 investors · BiotechnologyRule 506(b)
▶$4.4MraisedAug 2016 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roelof RongenExecutive Officer, Director
- Stefano FerrariDirector
- James ScibettaDirector
- Adam SternDirector
- Jerome JabbourExecutive Officer
- Herbert ConradDirector
- Abdel A. FawzyExecutive Officer
- Douglas F. KlingExecutive Officer
- Gary GaglioneExecutive Officer
- Raphael J. ManninoExecutive Officer
- Offering amount
- $8M
- Amount sold
- $4.4M
- Sales commissions
- $1M
- Placement agents
- Aegis Capital Corp.
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$10MraisedApr 2015 · 122 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2015 · 122 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jerome JabbourExecutive Officer
- Adam SternDirector
- George BobotasExecutive Officer
- Roelof RongenExecutive Officer, Director
- Gary GaglioneExecutive Officer
- Stefano FerrariDirector
- James ScibettaDirector
- Abdel A. FawzyExecutive Officer
- Herbert ConradDirector
- Douglas F. KlingExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1.3M
- Placement agents
- Aegis Capital Corp.
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
FoxbusinessFOX Business Network is a financial news channel that delivers real-time business and market information across multiple platforms. The network serves investors and business audiences interested in news affecting both retail and institutional markets.
Companies working in the same space as Matinas BioPharma Holdings.
Frequently asked questions
- What does Matinas BioPharma Holdings do?
- Matinas BioPharma develops a Lipid Nano-Crystal (LNC) drug delivery platform that enables oral, intracellular delivery of small molecules and oligonucleotides. Its lead product MAT2203 is an amphotericin B formulation, alongside discovery programs in oncology and inflammation.
- Who founded Matinas BioPharma Holdings?
- Matinas BioPharma Holdings was founded by Roelof Rongen, Jerome D. Jabbour in 2013.
- How much funding has Matinas BioPharma Holdings raised?
- Matinas BioPharma Holdings has disclosed $31.5M raised across 4 rounds.
- Where is Matinas BioPharma Holdings headquartered?
- Matinas BioPharma Holdings is headquartered in Bedminster, US.